Maximizing the potential of aggressive mouse tumor models in preclinical drug testing
Abstract Atypical teratoid rhabdoid tumor (ATRT) is an aggressive embryonal brain tumor among infants and young children. Two challenges exist for preclinical testing in ATRT. First, genetically quiet, ATRT is a difficult tumor to target molecularly. Tumor cells need to divide to propagate tumor gro...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-91167-6 |
id |
doaj-de5f4ee8efbe4626bc463e33bc5fd9a4 |
---|---|
record_format |
Article |
spelling |
doaj-de5f4ee8efbe4626bc463e33bc5fd9a42021-06-06T11:37:04ZengNature Publishing GroupScientific Reports2045-23222021-06-0111111510.1038/s41598-021-91167-6Maximizing the potential of aggressive mouse tumor models in preclinical drug testingM. Tarek Elghetany0Jia-Min Ho1Lois Hew Shi-Qi2Sekar Karthik3Jack M. F. Su4Qi Lin5YuChen Du6Jianhe Shen7Wing-Yuk Chow8Ching C. Lau9Adekunle Adesina10Angela Major11Anat Erdreich-Epstein12Kam-Man Hui13Xiao-Nan Li14Wan-Yee Teo15Baylor College of MedicineHumphrey Oei Institute of Cancer Research, National Cancer Center SingaporeHumphrey Oei Institute of Cancer Research, National Cancer Center SingaporeHumphrey Oei Institute of Cancer Research, National Cancer Center SingaporeBaylor College of MedicineAnn & Robert H. Lurie Children’s Hospital of ChicagoAnn & Robert H. Lurie Children’s Hospital of ChicagoBaylor College of MedicineBaylor College of MedicineBaylor College of MedicineBaylor College of MedicineBaylor College of MedicineDepartments of Pediatrics and Pathology, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, and the Keck School of Medicine, University of Southern CaliforniaHumphrey Oei Institute of Cancer Research, National Cancer Center SingaporeBaylor College of MedicineBaylor College of MedicineAbstract Atypical teratoid rhabdoid tumor (ATRT) is an aggressive embryonal brain tumor among infants and young children. Two challenges exist for preclinical testing in ATRT. First, genetically quiet, ATRT is a difficult tumor to target molecularly. Tumor cells need to divide to propagate tumor growth—intercepting the common crossroads in cell cycle progression is a feasible strategy. KIF11 is needed for bipolar spindle formation in metaphase. We identified KIF11 as a universal target of all ATRT-molecular-subtypes. Ispinesib, a KIF11-inhibitor, effectively inhibited tumor proliferation in all seven cell lines. A second challenge—a major challenge in preclinical drug testing in-vivo among aggressive tumor models, is the narrow therapeutic window to administer drugs within the limited murine lifespan. Our most aggressive ATRT tumor model was lethal in all mice within ~ 1 month of tumor implantation. Such short-surviving mouse models are difficult to employ for preclinical drug testing due to the narrow time window to administer drugs. To overcome this time restriction, we developed a clinical staging system which allowed physically-fit mice to continue treatment, in contrast to the conventional method of fixed drug-dose-duration regimen in preclinical testing which will not be feasible in such short-surviving mouse models. We validated this approach in a second embryonal brain tumor, medulloblastoma. This is a clinically relevant, cost-efficient approach in preclinical testing for cancer and non-cancer disease phenotypes. Widely used preclinical mouse models are not the most accurate and lack the aggressive tumor spectrum found within a single tumor type. Mice bearing the most aggressive tumor spectrum progress rapidly in the limited murine life-span, resulting in a narrow therapeutic window to administer drugs, and are thus difficult to employ in preclinical testing. Our approach overcomes this challenge. We discovered ispinesib is efficacious against two embryonal brain tumor types.https://doi.org/10.1038/s41598-021-91167-6 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
M. Tarek Elghetany Jia-Min Ho Lois Hew Shi-Qi Sekar Karthik Jack M. F. Su Qi Lin YuChen Du Jianhe Shen Wing-Yuk Chow Ching C. Lau Adekunle Adesina Angela Major Anat Erdreich-Epstein Kam-Man Hui Xiao-Nan Li Wan-Yee Teo |
spellingShingle |
M. Tarek Elghetany Jia-Min Ho Lois Hew Shi-Qi Sekar Karthik Jack M. F. Su Qi Lin YuChen Du Jianhe Shen Wing-Yuk Chow Ching C. Lau Adekunle Adesina Angela Major Anat Erdreich-Epstein Kam-Man Hui Xiao-Nan Li Wan-Yee Teo Maximizing the potential of aggressive mouse tumor models in preclinical drug testing Scientific Reports |
author_facet |
M. Tarek Elghetany Jia-Min Ho Lois Hew Shi-Qi Sekar Karthik Jack M. F. Su Qi Lin YuChen Du Jianhe Shen Wing-Yuk Chow Ching C. Lau Adekunle Adesina Angela Major Anat Erdreich-Epstein Kam-Man Hui Xiao-Nan Li Wan-Yee Teo |
author_sort |
M. Tarek Elghetany |
title |
Maximizing the potential of aggressive mouse tumor models in preclinical drug testing |
title_short |
Maximizing the potential of aggressive mouse tumor models in preclinical drug testing |
title_full |
Maximizing the potential of aggressive mouse tumor models in preclinical drug testing |
title_fullStr |
Maximizing the potential of aggressive mouse tumor models in preclinical drug testing |
title_full_unstemmed |
Maximizing the potential of aggressive mouse tumor models in preclinical drug testing |
title_sort |
maximizing the potential of aggressive mouse tumor models in preclinical drug testing |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2021-06-01 |
description |
Abstract Atypical teratoid rhabdoid tumor (ATRT) is an aggressive embryonal brain tumor among infants and young children. Two challenges exist for preclinical testing in ATRT. First, genetically quiet, ATRT is a difficult tumor to target molecularly. Tumor cells need to divide to propagate tumor growth—intercepting the common crossroads in cell cycle progression is a feasible strategy. KIF11 is needed for bipolar spindle formation in metaphase. We identified KIF11 as a universal target of all ATRT-molecular-subtypes. Ispinesib, a KIF11-inhibitor, effectively inhibited tumor proliferation in all seven cell lines. A second challenge—a major challenge in preclinical drug testing in-vivo among aggressive tumor models, is the narrow therapeutic window to administer drugs within the limited murine lifespan. Our most aggressive ATRT tumor model was lethal in all mice within ~ 1 month of tumor implantation. Such short-surviving mouse models are difficult to employ for preclinical drug testing due to the narrow time window to administer drugs. To overcome this time restriction, we developed a clinical staging system which allowed physically-fit mice to continue treatment, in contrast to the conventional method of fixed drug-dose-duration regimen in preclinical testing which will not be feasible in such short-surviving mouse models. We validated this approach in a second embryonal brain tumor, medulloblastoma. This is a clinically relevant, cost-efficient approach in preclinical testing for cancer and non-cancer disease phenotypes. Widely used preclinical mouse models are not the most accurate and lack the aggressive tumor spectrum found within a single tumor type. Mice bearing the most aggressive tumor spectrum progress rapidly in the limited murine life-span, resulting in a narrow therapeutic window to administer drugs, and are thus difficult to employ in preclinical testing. Our approach overcomes this challenge. We discovered ispinesib is efficacious against two embryonal brain tumor types. |
url |
https://doi.org/10.1038/s41598-021-91167-6 |
work_keys_str_mv |
AT mtarekelghetany maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT jiaminho maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT loishewshiqi maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT sekarkarthik maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT jackmfsu maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT qilin maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT yuchendu maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT jianheshen maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT wingyukchow maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT chingclau maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT adekunleadesina maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT angelamajor maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT anaterdreichepstein maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT kammanhui maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT xiaonanli maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting AT wanyeeteo maximizingthepotentialofaggressivemousetumormodelsinpreclinicaldrugtesting |
_version_ |
1721393894406488064 |